Drug intelligence / Profile preview

SYN116

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

SYN116 is a small molecule drug that acts as an antagonist of the prostacyclin (PGI2) receptor, also known as the prostanoid IP receptor. It was initially developed by F. Hoffmann-La Roche and later involved organizations such as Acorda Therapeutics and Biotie Therapies Oy. The primary therapeutic area explored for SYN116 was nervous system diseases, with clinical development focused on pain management. Its mechanism involves blocking the PGI2 receptor to modulate pain signaling pathways in the nervous system. Development of SYN116 has been discontinued after reaching Phase 1 clinical trials[1].

Targets

PTGIR (Prostanoid IP Receptor)

Beyond the preview

Go deeper on SYN116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYN116.

Explore the full profile